Clinical trial
The Study of GM1 Ganglioside, A Potential New Parkinson's Disease Medication
NCT00037830 is registered in ClinicalTrials.gov with Thomas Jefferson University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Study of GM1 Ganglioside, A Potential New Parkinson's Disease Medication
- Lead sponsor
- Thomas Jefferson University
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- November 30, 1999
- Completion date
- June 30, 2010
- Enrollment
- 94 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.